Last week, Incyte's (NASDAQ: INCY)IDO inhibitor epacadostat failed a phase 3 study in a major way, and shareholders are really feeling it. In this segment from Industry Focus: Healthcare , analysts Michael Douglass and Shannon Jones explain what happened.
What Happened With Incyte's IDO Inhibitor Flop
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться